The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism

European Journal of Clinical Pharmacology

Volumn 53, Issue 3-4, 1997, Pages 261-264

  Kortunay, S ^a   Basci, N E ^a   Bozkurt, A ^a   Isimer, A ^b   Sayal, A ^b   Kayaalp, S O ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

CYP2C19; Omeprazole

Indexed keywords

CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; MEPHENYTOIN; OMEPRAZOLE; PROGUANIL;

ADULT; AEROBIC METABOLISM; ARTICLE; CLINICAL TRIAL; DRUG HYDROXYLATION; DRUG METABOLISM; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; TURKEY (REPUBLIC); VOLUNTEER;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CHLOROGUANIDE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROXYLATION; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; OMEPRAZOLE;

EID: 0031460883     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050373     Document Type: Article

References (21)

1. Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537
2. Brosen K, Skjelho E, Flacks H (1993) Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 36: 105-108
3. Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin a new drug hydroxylation polymorphism in man. Eur J Pharmacol 26: 753-759
4. Bertilsson L, Kalow W (1993) Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther 53: 608-610
5. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM (1991) The activation of the biguanid anti-malarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 31: 689-692
6. Balain JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, Flockhart DA (1995) The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 57: 662-669
7. Chang M, Dahl M, Tybring G, Götharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5: 358-363
8. deMorais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UR, Goldstein JA (1994). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 22: 15419-15422
9. deMorais SMF, Grant RW, Blaisdell J, Meyer UA, Nakamura K, Goldstein J (1994). Identification of a new genetic defect for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598
10. Brosen K, deMorais SMF, Meyer UA, Goldstein JA (1995) A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 5: 312-317
11. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T (1992) Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 262: 1195-1202
12. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L (1992) Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2: 25-31
13. Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Owen R, Flockhart DA (1996) Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 60: 138-144
14. 18 column. J Chromatogr 579: 299-305
15. Skjelbo E, Mutabingwa TK, Bygbjerg I, Nielsen KK, Gram LF, Brosen K (1996) Proguanil metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 59: 304-311
16. Basci NE, Bozkurt A, Kortunay S, Isimer A, Sayal A, Kayaalp SO (1996) Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Br J Clin Pharmacol 42: 771-773
17. Sanz EJ, Villen T, Alm C, Bertilsson L (1989) S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45: 495-499
18. Basci NE, Brosen K, Bozkurt A, Isimer A, Sayal A, Kayaalp SO (1994) S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphism in a Turkish population. Br J Clin Pharmacol 38: 463-465
19. Evans DAP, Harmer D, Downham DY, Whibley EJ, Idle JR, Ritchie J, Smith RL (1983) The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distribution. J Med Genetics 20: 321-329
20. Woolhouse NM, Eichelboum M, Oates NS, Idle JR, Smith RL (1985) Dissociation of co-regulator control of debrisoquine/ phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 37: 512-521
21. Bozkurt A., Başçi NE, Işimer A, Sayal A, Kayaalp SO (1996) Metabolic rates of four probes of CYP2D6 in Turkish subjects: a cross over study. Eur J Drug Metab Pharmacokinet 21: 309-314